Develops bispecific antibodies for non-small cell lung cancer.
Dec 2024Revenue $0.00/yrExpenses $226M/yr
Fell below break-even Apr 2019Cash runway ≈ 1.5 years from Jun 2026
Figures by year
When will Summit Therapeutics be profitable again?
Its expenses passed its revenue in Apr 2019. In the 12 months to Dec 2024, revenue was $0.00 and expenses $226M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $0.00 | $226M | −$226M |
| Dec 2023 | $0.00 | $610M | −$610M |
| Dec 2022 | $705K | $72.8M | −$72.1M |
| Dec 2021 | $1.81M | $88.0M | −$86.2M |
| Dec 2020 | $860K | $54.1M | −$53.2M |
| Jan 2019 | $57.1M | $51.7M | $5.39M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.